Literature DB >> 15588347

The cross-clade neutralizing activity of a human monoclonal antibody is determined by the GPGR V3 motif of HIV type 1.

Susan Zolla-Pazner1, Ping Zhong, Kathy Revesz, Barbara Volsky, Constance Williams, Phillipe Nyambi, Miroslaw K Gorny.   

Abstract

Both polyclonal and monoclonal human antibodies (Abs) to the V3 domain of HIV-1 gp120 display cross-clade neutralizing activity against primary isolates and T cell-adapted virus strains. The most broadly neutralizing of the human anti-V3 monoclonal Abs (mAbs), 447-52D, recognizes 14 amino acids, including the GPxR core epitope at the tip of the V3 loop. Monoclonal Ab 447-52D neutralized 92% of 38 primary isolates carrying the GPGR V3 motif regardless of whether the viruses belonged to clades A, B, F, or H; in contrast, none of 19 viruses with the GPGQ and other non-GPGR/Q sequences at the tip of the V3 loop was sensitive to mAb 447-52D. These data are consistent with the crystallographic resolution of a complex of the Fab fragment of mAb 447-52D with a V3 peptide that shows that the binding specificity of the mAb is due to recognition of the GPGR motif at the tip of the loop. The critical role of the Arg residue in this motif was determined using viruses pseudotyped with the envelope of primary isolate CA1 containing the GPGR motif or with a mutated envelope with a Gln (Q) replacing the Arg (R) at the tip of the loop. While the wild-type pseudovirus was neutralized by mAb 447-52D, the pseudovirus carrying the point mutation was resistant to neutralization. These data illuminate the structural basis for both the breadth and specificity of a broadly neutralizing human mAb and contribute to our understanding of the epitopes recognized by Abs that protect against infection with HIV-1.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15588347     DOI: 10.1089/aid.2004.20.1254

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  54 in total

1.  Conserved structural elements in the V3 crown of HIV-1 gp120.

Authors:  Xunqing Jiang; Valicia Burke; Maxim Totrov; Constance Williams; Timothy Cardozo; Miroslaw K Gorny; Susan Zolla-Pazner; Xiang-Peng Kong
Journal:  Nat Struct Mol Biol       Date:  2010-07-11       Impact factor: 15.369

2.  Cross-clade neutralizing activity of human anti-V3 monoclonal antibodies derived from the cells of individuals infected with non-B clades of human immunodeficiency virus type 1.

Authors:  Miroslaw K Gorny; Constance Williams; Barbara Volsky; Kathy Revesz; Xiao-Hong Wang; Sherri Burda; Tetsuya Kimura; Frank A J Konings; Arthur Nádas; Christopher A Anyangwe; Phillipe Nyambi; Chavdar Krachmarov; Abraham Pinter; Susan Zolla-Pazner
Journal:  J Virol       Date:  2006-07       Impact factor: 5.103

3.  Evidence for potent autologous neutralizing antibody titers and compact envelopes in early infection with subtype C human immunodeficiency virus type 1.

Authors:  Bing Li; Julie M Decker; Roy W Johnson; Frederic Bibollet-Ruche; Xiping Wei; Joseph Mulenga; Susan Allen; Eric Hunter; Beatrice H Hahn; George M Shaw; Jerry L Blackwell; Cynthia A Derdeyn
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

4.  A group M consensus envelope glycoprotein induces antibodies that neutralize subsets of subtype B and C HIV-1 primary viruses.

Authors:  Hua-Xin Liao; Laura L Sutherland; Shi-Mao Xia; Mary E Brock; Richard M Scearce; Stacie Vanleeuwen; S Munir Alam; Mildred McAdams; Eric A Weaver; Zenaido Camacho; Ben-Jiang Ma; Yingying Li; Julie M Decker; Gary J Nabel; David C Montefiori; Beatrice H Hahn; Bette T Korber; Feng Gao; Barton F Haynes
Journal:  Virology       Date:  2006-09-30       Impact factor: 3.616

5.  Analysis of the neutralization breadth of the anti-V3 antibody F425-B4e8 and re-assessment of its epitope fine specificity by scanning mutagenesis.

Authors:  Ralph Pantophlet; Rowena O Aguilar-Sino; Terri Wrin; Lisa A Cavacini; Dennis R Burton
Journal:  Virology       Date:  2007-04-06       Impact factor: 3.616

6.  Isolation and characterization of monoclonal antibodies elicited by trimeric HIV-1 Env gp140 protein immunogens.

Authors:  Nina R Derby; Sean Gray; Elizabeth Wayner; Dwayne Campogan; Giorgos Vlahogiannis; Zane Kraft; Susan W Barnett; Indresh K Srivastava; Leonidas Stamatatos
Journal:  Virology       Date:  2007-06-08       Impact factor: 3.616

7.  Subtype-specific conformational differences within the V3 region of subtype B and subtype C human immunodeficiency virus type 1 Env proteins.

Authors:  Milloni B Patel; Noah G Hoffman; Ronald Swanstrom
Journal:  J Virol       Date:  2007-11-14       Impact factor: 5.103

8.  Structure determination of an anti-HIV-1 Fab 447-52D-peptide complex from an epitaxially twinned data set.

Authors:  Amandeep K Dhillon; Robyn L Stanfield; Miroslaw K Gorny; Constance Williams; Susan Zolla-Pazner; Ian A Wilson
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2008-06-18

9.  Neutralizing activity of antibodies to the V3 loop region of HIV-1 gp120 relative to their epitope fine specificity.

Authors:  Ralph Pantophlet; Terri Wrin; Lisa A Cavacini; James E Robinson; Dennis R Burton
Journal:  Virology       Date:  2008-09-26       Impact factor: 3.616

10.  Betulinic acid derivatives that target gp120 and inhibit multiple genetic subtypes of human immunodeficiency virus type 1.

Authors:  Weihong Lai; Li Huang; Phong Ho; Zhijun Li; David Montefiori; Chin-Ho Chen
Journal:  Antimicrob Agents Chemother       Date:  2007-10-22       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.